Abstract
SummaryLung cancer is still one of the most common cancer entities worldwide and the leading cause of cancer mortality. Despite significant advances in the diagnosis and therapy of lung cancer, many patients do not respond to existing therapies, indicating an urgent need for the development of novel treatment strategies. In recent years, nanotechnology has led to significant progress in modern medicine. Especially lipid nanoparticles (LNPs) evoked substantial interest, due to their broad application as coronavirus disease 2019 (COVID-19) vaccines. In the future of lung cancer treatment, lipid nanoparticles hold the potential to provide specific, safe, and well-tolerated treatments by incorporating multiple drugs and targeting agents and enabling their trafficking to tissues or cell types of interest. This review briefly summarizes the application of LNPs in lung cancer treatment as well as their future possibilities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
